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| INTRODUC TI ON
Pruritus is defined as an unpleasant perception that provokes the desire to scratch to itch. Often resulting from the activation of free nerve endings by pruritogenic, or itch inducing, stimuli in the skin and regarded as an ancient self-defense mechanism among nearly all mammals to remove the pruritogenic stimuli, pruritus is a common feature of many inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (Pso). In skin, the propagation of itch can result from both inflammatory (eg, AD, Pso) and noninflammatory diseases (eg, uremic pruritus, cholestatic pruritus). 1 Both AD and Pso are prototypic inflammatory skin diseases that are accompanied by pruritus. AD and Pso are complex diseases with genetic, 2 immunological, 3 and environmental 4 contributions. Less understood perhaps are the roles of neuronal sensitization and skin barrier disruptions which likely contribute to pruritus as well. In this review article, we will focus predominantly on the similarities and, importantly, differences in pruritus between AD and Pso. This comparison will not only help define the mechanisms underlying pruritus but also contribute to specific therapeutic targets of pruritus in these two common skin diseases.
| ITCHING IN ATOPI C DERMATITIS

| Itch characteristics in AD
Atopic dermatitis is a chronic relapsing disease with intense itch that is felt by early all affected individuals. In early characterizations of AD, itching was an essential symptom for the diagnosis of AD. 5 Others have defined AD by the presence of elevated immunoglobulin E (IgE) and pruritus that is often accompanied by other allergic diseases. 6, 7 Different from Pso, AD generally develops in early childhood with 90% of patients demonstrating onset within the first 5 years of life. 8 Itch is a nearly universal feature of AD and is an essential clinical component in most diagnostic criteria. [9] [10] [11] The itch in AD is often characterized by patients as burning and stinging, suggesting a neurogenic origin. 12 The pruritus can be intense even when there are no visible skin lesions. In fact, AD is commonly referred as "the itch that rashes," which reflects itch often precedes skin lesions in AD. 13, 14 Sleep disturbance due to itch is common in patients with AD, and this itch is often exacerbated at night in a circadian manner. 15 Furthermore, transepidermal water loss (TEWL) is associated with itch intensity in AD, 16 and TEWL increases at night in patients with AD, which may explain why AD patients have nocturnal bouts of itch. 17 Moreover, patients with AD often develop lesions on flexor surfaces, which has led others to suggest that sweating may play a role in the pathogenesis of AD. 18 The pruritus in AD is very difficult to treat and does not respond well to traditional antipruritic treatments such as oral antihistamines. 1 There is an "itch-scratch cycle" that exacerbates skin lesions and pruritus. 19 Mechanical scratching due to itch eventuates in secondary rash and occasional infection or colonization with microorganisms, particularly Staphylococcus aureus (S. aureus), 20 which further aggravates the disease course. It is often observed that patients with AD present with initial edema, erythema, and papules, progressing to secondary skin lesions such as lichenification, exudation, and crusting. As mentioned before, itching often precedes visible dermatitis. The sequential change of the skin lesions reflects the effect of pruritus and scratching in the course of disease development. Scratching-induced lesions are more frequently observed in AD than Pso. Among these scratch-induced lesions, lichenification is more common in AD (80%) compared with Pso (33%). 21 Dryness and sweating are important triggers for AD flares, and there is a positive relationship between SCORing Atopic Dermatitis (SCORAD) and itch intensity. 
| Immune mechanisms of pruritus in AD
The precise allergens in most patients with AD are not known, but AD in some patients is associated with house dust mite and fungal allergens. 23 After allergens penetrate the impaired skin barrier, they bind to Langerhans cells and activate Th2 cells to release inflammatory cytokines mainly IL-4 and IL-13. These cytokines stimulate
IgE production and reduce production of antimicrobial peptides, which may facilitate microbial infections such as S. aureus. 24, 25 Research has indicated microbial infections such as S. aureus emerge during the onset of atopic dermatitis, and antibiotic treatments for these microbial infections eliminated skin inflammation. 
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Th2 cells also release IL-31, a recently identified member of the IL-6 family, that can be a critical driver of pruritus in AD, [29] [30] [31] but is generally not thought to be expressed at high levels in the skin of Pso patients. 32 In mice, IL-31 induces pruritus through IL-31 receptors that are expressed by the primary afferent neurons, mediating action through the TRPV1 and TRPA1 ion channels. 32 In humans, IL-31 injection evoked delayed onset itch, implicating an indirect pruritogenic mechanism. 33 It has been proposed that IL-31 induces pruritus indirectly via keratinocytes and subsequently released secondary mediators such as vascular endothelial growth factor (VEGF). 34, 35 IL-31 also promotes β-endorphin production by keratinocytes to transmit itch sensation. 31 IL-31 also remodels and thickens the epidermis which leads to impaired skin barrier function resulting in an increased TEWL. 
| Ion channels and neuropeptides in AD
The transient receptor potential (TRP) channels are a family of ion channels with a myriad of roles, many of which act as biological sensors for heat, cold, pressure, osmolarity, and chemicals. 46 TRPV1 in small-to-medium diameter dorsal root ganglion (DRG)
neurons. 53 TRPA1 expression is highly enhanced in the dermal afferent nerves, their dorsal root ganglia, mast cells, and the epidermis in the lesional skin biopsies from patients with AD, compared with skin from healthy subjects. 54, 55 In AD, neuropeptides such as substance P (SP), calcitonin generelated peptide (CGRP), and nerve growth factor (NGF) play an important role in cross-talk between the immune and nervous systems. 55, 57 CGRP can increase the production of IL-13 from cutaneous lymphocyte-associated antigen (CLA)+ T cells and induce an immune shift from a Th1 to a Th2 cytokine profile. 58 The IL-13 cytokine stimulates expression of TRPA1 on tryptase-positive mast cells, which can act on afferent nerves to transmit itch. 54 NGF plays an important role in inflammatory disease and is increased in the plasma and lesion site of AD. 59 The increased nerve density in AD lesions is partly mediated by the release of NGF by keratinocytes. 55 NGF binds to its high-affinity receptor tropomyosin receptor kinase A (TrkA), which sensitizes and sprouts the small diameter sensory neurons, and upregulates the expression and sensitivity of TRPV1 via TrkA on sensory neurons. 60 The NGFTrkA-TRPV1 signaling loop is regarded as a key mechanism of itch in many of the inflammatory diseases, including Pso and AD. Gastrinreleasing peptide (GRP) and gastrin-releasing peptide receptor (GRPR) are involved in sensation of itch, but their role in AD remains unclear. 55 GRP, which is released by neurons in dorsal root ganglion, activates GRPR on spinal interneurons and transmits itch. 61 Severity of pruritus in AD correlates with serum GRP levels. 62 Table 1 shows neuropeptides that are involved in pruritogenic signaling in AD.
| The relationship among keratinocytes, nervous system, and the immune system in AD
The mechanism of chronic itch in AD is a complex cross-talk between keratinocytes, neurons, and immune system. Keratinocytes and immune cells can release inflammatory mediators such as cytokines, histamine, and serotonin. Many of these inflammatory mediators can activate sensory nerves to mediate itch in the skin. 63 Sensory neurons released neuropeptides such as SP and CGRP that stimulate keratinocytes to secrete NGF, which in turn promotes proliferation of keratinocytes and hyperinnervation of sensory neurons. SP and CGRP also act on Th2 cells to skew inflammation and act on mast cell to induce degranulation. 63 The communication between skin and the nervous system is not restricted to the peripheral nervous system. Neurodegenerative diseases such as Parkinson's disease and dementia are more prevalent in elderly patients who met diagnostic criteria of AD. 64 The exact mechanism underlying this phenomenon is unclear, but it has been reported that BP180-and BP230-specific IgG autoantibodies are associated with pruritus in elderly patients. 65 Immunosenescence of T cells may result in a loss of immune tolerance and the development of BP180-and BP230-specific IgG autoantibodies. This, in turn, may lead to a chronic generalized eczema mimicking atopic dermatitis that may be regarded as a preclinical variant of bullous pemphigoid. [64] [65] [66] Another connection between skin and the nervous system which contributes to pathophysiology of AD lies in circadian rhythms.
Circadian rhythm is a biological clock that controls physiological functions throughout the body. 67 Skin physiology parameters such as TEWL and cutaneous blood flow fluctuate with circadian rhythm. 67 AD often exacerbates at night, and this phenomenon is related to increased TEWL at nighttime. 17 Melatonin is a hormone mainly secreted by pineal gland that regulates the circadian rhythm and sleep. 68 The circadian melatonin rhythm was abolished or diminished in patients with AD, 69 and melatonin supplementation has been demonstrated as an effective way to improve AD severity in children. 
| Itch characteristics in Pso
Pso is an immune-mediated chronic inflammatory disease that commonly affects the skin and, in a minority of patients, affects the joints. Pso affects approximately 2%-11% of Caucasian populations while its prevalence is around 0.24%-5.5% in Asian populations. 73 Patients with an early onset tend to have a more severe course and a positive family history, whereas patients with late onset have a more mild disease and often have a negative family history. 74 In the last decade, it has become clear that Pso is a systemic disease with multiple comorbidities, including enhanced cardiovascular risk, obesity, and psychiatric disorders. [75] [76] [77] Itch exacerbates patients' quality of life and may account for increased psychological burden and psychiatric comorbidities of Pso. 78, 79 Despite its name (psoriasis is derived from "psor", Greek, to itch), pruritus is not regarded as a universal symptom of Pso since pruritus affects ~60-90% of patients, 80 especially females. 81 The itching sensations are not limited to lesional areas and often include areas on the scalp, groin, and buttocks. 82 Itch also induces scratching and leads to damage to the skin and development of Koebner phenomenon. Therefore, relief of itch is very important for treatment of Pso.
Compared with patients with AD, however, patients with Pso experience fewer problems with insomnia and sleep quality. 83 A systemic review reported that the prevalence of insomnia in patients with Pso is similar to that in the general population. 84 Much of the pathogenesis of pruritus in Pso remains to be elucidated, but neurogenic inflammation seems to be crucial. 80 In contrast to AD patients, Pso patients rarely complain of itching in the absence of obvious skin redness and scaling. The number of epidermal nerve fibers is increased in skin lesions of psoriatic patients with pruritus. 91 The sensory nerve fibers in the skin not only mediate pruriception but also release bioactive substances such as SP, which can mediate the inflammation and is responsible for the itching sensation in Pso. The active form SP cleaved by dipeptidyl peptidase IV (DPPIV) is increased in sera of patients of Pso. DPPIV-knockout mice and mice treated with DPPIV inhibitors show decreased SP-induced scratching behavior. 92 There is also enhanced growth of nerve Cfibers found in Pso. 93 Another neuropeptide important for Pso is NGF, which can trigger the outgrowth of C-fibers, leading to pruritus. NGF and platelet-derived growth factor (PDGF) with some cytokines such as IL-17 and IL-22 activate phosphatidylinositol 3-kinase (PI3K)-AKT-mTOR kinase system, elucidating the inflammatory and proliferative cascades. heterodimerizes with the GRPR and is internalized to evoke itch. 97 In AD, IL-31 induces production of β-endorphins and the blood level of β-endorphins correlate with itch intensity. 16, 31 Recently, it has been reported that the κ-opioid receptor pathway is downregulated in lesional skin of Pso patients and positively correlate with itch sensation. In contrast, the μ-opioid receptor pathway is uniformly expressed by epidermal keratinocytes of psoriatic skin. 98 Taken together, these findings suggest that homeostasis of epidermal opioid receptors may be involved in the generation of itch in both AD and Pso. 99 
| Immune mediators and neuropeptides in the pathogenesis of pruritus in psoriasis
| Ion channels in the pathogenesis of pruritus in Pso
The ion channels are known to participate in the itch of cutaneous neurogenic inflammation, which is related to itch. TRPV1 and TRPA1
are not only expressed in neuronal cells, which exist in cutaneous Cand Aδ-type sensory nerve endings, but are also expressed in nonneuronal cells such as keratinocytes. 46 The pathway. 100 As in AD, the NGF-TrkA-TRPV1 interaction partially mediates pruritus in Pso. A topical TrkA inhibitor, CT327, has been reported to reduce pruritus in patients with Pso. 101 Our recent studies showed that TRPV1 knockout mice have significantly reduced epidermal and dermal inflammation and TEWL compared to wildtype mice in the IMQ-mediated model of psoriasiform dermatitis. 102 We did not see marked changes in behavior signs of pruritus in the TRPV1 knockout mice under the same conditions, suggesting that dermal inflammation and pruritus can be independently mediated in some cases (manuscript submitted).
The role of TRPA1 in mediating pruritus of Pso is not as well defined. TRPA1 is generally regarded as a contributor of chronic pruritus. 103 Activation of TRPA1 triggers the expression of Psorelated genes, including IL-33, CCL20, CXCL2, CXCR2, lipocalin, and Slc9a3r1. 103 In a topical imiquimod-induced murine model of psoriasiform dermatitis, spontaneous scratching to the imiquimod-treated sites and alloknesis are observed. 104 In that study, no significant change in the mRNA expression of TRPV1 or TRPA1 in DRG cells was observed. The mRNA expression levels of histidine decarboxylase and tryptophan hydroxylase 1, as well as the intensity of histamine and serotonin immunoreactivity, transiently increased in the skin but returned to baseline by the end of imiquimod 7-day treatment course. In parallel with that finding, histamine H1-receptor antagonists significantly inhibited spontaneous scratching on day 2, but not day 7. These results may explain the limited antipruritic effects of histamine H1-receptor antagonists in human Pso. 104 In a recent article, TRPA1 is reported to act in a protective manner in an imiquimod murine model of psoriasiform dermatitis. 105 Intriguingly,
another study using the same imiquimod murine model found that blockade, either genetic or pharmacological approaches, of common sensory neurogenic mechanisms for TRPV1, TRPA1, SP, and CGRP inhibits spontaneous biting/licking behaviors, which are indicative of cutaneous discomfort. 106 This indicates neuropeptides-ion channels signaling can induce cutaneous discomfort, but its role in psoriatic inflammation, either pro-inflammation or anti-inflammation, remains to be clarified.
| TRE ATMENT OF PRURITUS FOR AD AND PSO
For mild disease in both AD and Pso, topical corticosteroids re- It not only has a dramatic antipruritic effect but also decreases the anxiety or depression associated with AD. 107 Inhibitors of IL-31
| Biologic agents
(nemolizumab) 109, 110 and IL-13 (lebrikizumab, tralokinumab) 111, 112 have had promising results from phase 2 clinical trials for patients with moderate-to-severe AD. Fezakinumab, an IL-22 monoclonal antibody, showed efficacy only for severe AD (SCORAD ≥50) in a phase 2 clinical trial. 113 Another report suggested that fezakinumab may be more effected for patients with high baseline IL-22 expression. 114 Interestingly, selective targeting of some propruritogenic factors such as TSLP has shown mixed results in clinical testing. For example, the anti-TSLP monoclonal antibody, tezepelumab, showed efficacy for uncontrolled asthma in a phase 2 clinical trial, 115 but its efficacy for atopic dermatitis has not been validated. 116 Omalizumab, which targets IgE, is currently undergoing a clinical trial to determine its efficacy for severe recalcitrant pediatric AD. 117 Other anti-IgE agents such as MEDI4212 and ligelizumab have undergone phase 1 clinical trials but their efficacy for AD has yet to be evaluated.
118,119
| Small molecule drugs
Phosphodiesterase 4 (PDE4) is an enzyme which degrades cyclic adenosine monophosphate (cAMP). Apremilast is an oral PDE4 inhibitor that is used for treatment for immune-mediated diseases, including Pso, although its clinical efficacy is not as great as those of biological agents. 120 Crisaborole ointment is a FDA-approved topical PDE4
inhibitor for the treatment of mild-to-moderate AD. 121 Interestingly, apremilast is not considered to be effective for AD. 
| Ion channel inhibitors and potential targeted therapies
NGF-TrkA-TRPV1 partially mediates pruritus in AD and Pso. The amount of NGF is 10 times higher in keratinocyte cultures of Pso compared to the healthy individuals. 137 Topical TrkA inhibitor CT327
showed significant clinical effect in reducing chronic pruritus in Pso patients. 101 In AD, TrkA is expressed in all layers of keratinocytes.
Th2 cytokines such as IL-4 and IL-13 enhance TrkA expression. 49 It not only blocks Ca2+ influx into keratinocytes and accelerates skin barrier repair but also suppresses the degranulation of mast cells and decreases the serum IgE, which in turn blocks the downstream inflammatory response and relieves the itching and controls the scratching behavior. Suppression of TRPV1 activation in nerve fibers can decrease neuropeptide release, contributing to the alleviation the cutaneous neurogenic inflammation. 139 While PAC-14028 shows promise, another TRPV1 inhibitor SB705498 shows no effect on itch relief. 140 JAK inhibitors oclacitinib and tofacitinib can decrease itch in AD and Pso, which are linked with the inhibition of TRPV1 receptor channels.
141
While TRPV1 is necessary for histaminergic itch, TRPA1 is necessary for many types of itch that are independent from histamine (nonhistaminergic itch) including TSLP-induced itch. 71 The PAR2/ TRPA1 pathway maybe a potential target for treating AD itch. 142 Although a TRPA1 inhibitor has not been used to treat itch clinically, recent work has shown that IL-13 induces chronic pruritus in AD via a novel TRPA1-dependent pathway, and a TRPA1 antagonist alleviated pruritus in AD mice. 54 
| CON CLUS IONS
AD and Pso are prototypic inflammatory skin diseases that are characterized by intense pruritus. It is tempting to speculate that neurogenic itching may precede obvious cutaneous inflammation (and skin changes) in AD, which is radically different from the itching that generally follows obvious dermatitis in Pso. Although AD is traditionally regarded as Th2 predominant and Pso is Th17 predominant, recent research shows these two diseases have some common immune pathways, at least in certain subtypes of AD. 38 Understanding of the similarities and discrepancy between AD and Pso would lead to development of treatments that are efficacious for both diseases or specific to either one. While inhibiting inflammation would generally reduce pruritus in AD and Pso, there is evidence that certain cytokine and neuropeptides-ion channels signaling can induce pruritus that is independent of inflammation in AD and Pso. 71, 106, 143 Curiously, there are AD patients who have generalized pruritus with no or minimal dermatitis. Current therapies are truly lacking to adequately manage these patients in which topical corticosteroids are not particularly effective. Agents therefore that target itch pathways may be more appropriate. More specifically, TRPV1-and TRPA1-associated signaling pathways are potential therapeutic targets to inhibit pruritus. 54, 101, 141 Current treatments for AD and Pso focus on inhibiting immunemediated inflammation. Further understanding of admittedly complex pruritogenic signaling pathways would help develop tailored treatment to reduce pruritus to improve patient quality of life.
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